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BET family proteins are novel therapeutic targets
for cancer and inflammation and represent the first
chromatin readers against which small-molecule
inhibitors have been developed. First-generation
BET inhibitors have shown therapeutic efficacy in
preclinical models, but the consequences of sus-
tainedBET protein inhibition in normal tissues remain
poorly characterized. Using an inducible and revers-
ible transgenic RNAi mouse model, we show that
strong suppression of the BET protein Brd4 in adult
animals has dramatic effects in multiple tissues.
Brd4-depleted mice display reversible epidermal
hyperplasia, alopecia, and decreased cellular diver-
sity and stem cell depletion in the small intestine.
Furthermore, Brd4-suppressed intestines are sensi-
tive to organ stress and show impaired regeneration
following irradiation, suggesting that concurrent
Brd4 suppression and certain cytotoxic therapies
may induce undesirable synergistic effects. These
findings provide important insight into Brd4 function
in normal tissues and, importantly, predict several
potential outcomes associated with potent and sus-
tained BET protein inhibition.INTRODUCTION
The bromodomain and extraterminal (BET) family of chromatin
reader proteins are an exciting new class of therapeutic targets
in inflammation and in solid and hematopoietic cancers. Devel-
opment and optimization of small molecules that antagonize
BET activity (Filippakopoulos et al., 2010; Nicodeme et al.,Cell Re2010) has led to the initiation of phase 1/2 clinical trials, yet we
know surprisingly little about the consequences of disrupting
BET protein function in normal tissues. Brd4 is one of four
mammalian BET familymembers, which, through its dual bromo-
domains, recognizes and binds acetyl-lysine residues of histone
and nonhistone proteins (Wu and Chiang 2007). Brd4 serves as a
chromatin scaffold, enabling the recruitment of transcription
factors, transcriptional coactivators and corepressors, and
core transcriptional machinery to acetylated target gene pro-
moters (Belkina and Denis 2012). Brd4 thereby regulates diverse
biological processes, including the cell cycle (Dey et al., 2009),
inflammation (Huang et al., 2009; Nicodeme et al., 2010), main-
tenance of higher-order chromatin structure (Wang et al.,
2012), and DNA damage signaling (Floyd et al., 2013).
An immediate rationale for the development of BET/Brd4
inhibitors was provided by the discovery of recurrent t(15;19)
chromosomal translocations (and the resulting in-frame fusion
of Brd4 and nuclear protein in testis [NUT]) as the cause of
NUT midline carcinoma (NMC) (Filippakopoulos et al., 2010;
French et al., 2001). The subsequent identification of Brd4 as
an important maintenance gene in acute myeloid leukemia
(AML) fueled further interest in Brd4 as a cancer target (Zuber
et al., 2011b). First-generation synthetic BET inhibitors, such
as JQ1, mimic acetylated-lysine moieties and bind to the bromo-
domain pockets of all four BET family members (Brd2, Brd3,
Brd4, and BrdT) (Filippakopoulos et al., 2010, Nicodeme et al.,
2010). Such inhibitors have demonstrated anticancer activity in
preclinical murine and xenograft models of NMC, AML, multiple
myeloma, and Burkitt’s lymphoma (Delmore et al., 2011; Filippa-
kopoulos et al., 2010; Mertz et al., 2011; Zuber et al., 2011b), and
their derivatives have entered phase 1/2 clinical trials for the
treatment of NMC and hematological malignancies (Mirguet
et al., 2013).
In AML, BET inhibitors are thought to act largely by inhibiting
the expression of c-Myc and, consequently, block the self-
renewal and survival of leukemia cells (Delmore et al., 2011;ports 8, 1919–1929, September 25, 2014 ª2014 The Authors 1919
Grayson et al., 2014; Mertz et al., 2011; Zuber et al., 2011b). As
such, these agents provide a unique opportunity to inhibit this
undruggable transcription factor. However, in nonhematological
cancers and noncancer pathologies (i.e., inflammation), BET in-
hibitors appear to suppress the function of other transcriptions
such as FOSL1 and NF-kB (Huang et al., 2009; Lockwood
et al., 2012). Although less is known about BET action in normal
tissues, mice null for Brd4 die early after implantation and
heterozygote Brd4+/ mice exhibit higher rates of postnatal
death, reduced growth rates, and a variety of serious develop-
mental abnormalities (Houzelstein et al., 2002). While these
observations raise toxicity concerns, preclinical tests with first-
generation pan-BET inhibitors indicate that mice can tolerate
therapeutic doses of JQ1 for up to 3 months (Matzuk et al.,
2012). However, the pharmacokinetic properties of the first-gen-
eration compounds did not allow sustained target inhibition and
thus showed limited efficacy. Therefore, the full range of poten-
tial toxicities that might be encountered upon achieving sus-
tained target inhibition has not yet been reported.
Our laboratory recently described a platform for the produc-
tion of transgenic mice harboring tetracycline/doxycycline
(dox)-responsive short hairpin RNAs (shRNAs) that allow tempo-
ral and spatial control of endogenous gene expression. Impor-
tantly, since shRNAs do not modify the genomic loci of target
genes, the system enables transient, reversible gene silencing
(Dow et al., 2012; Premsrirut et al., 2011), thereby facilitating
genetic loss-of-function studies as well as an assessment of
reversible and irreversible phenotypes simply by adding and
removing dox from the diet. When applied to candidate drug
targets, such models can point toward potential toxicities asso-
ciated with on-target gene inhibition, determine the kinetics of
their appearance precisely from target knockdown, and evaluate
whether any or all are reversible. Here, we used this approach to
identify consequences of Brd4 suppression in adult tissues and
observed significant yet reversible deleterious phenotypes that
should inform clinical use of BET inhibitors.
RESULTS
Brd4 Suppression Alters Normal Hematopoiesis
BET inhibitors are entering phase 1/2 clinical trials for the
treatment of hematological malignancies, yet little is known
about how they impact normal hematopoietic development. To
examine the consequence of Brd4 suppression on normal hema-
topoiesis, we performed a two-color competitive reconstitution
assay, which measures the in vivo ‘‘fitness’’ of cells harboring
experimental shRNAs (marked by GFP fluorescence) against
cells expressing a neutral shRNA targeting Renilla luciferase
(marked by mCherry) (Figure 1A) (Zuber et al., 2011a). To mini-
mize the possibility that any effects could be due to ‘‘off-target’’
silencing, we performed reconstitutions with two independent
Brd4 shRNAs (shBrd4.1448 and shBrd4.552) (Figure S1A),
previously shown to potently inhibit Brd4 expression in AML
cells (Zuber et al., 2011b). Importantly, in vitro RNAi-mediated
silencing of Brd4 produces a gene expression profile similar to
that of treatment with the BET inhibitor JQ1, suggesting that
RNAi is a suitable surrogate for Brd4-targeted drugs (Zuber
et al., 2011b).1920 Cell Reports 8, 1919–1929, September 25, 2014 ª2014 The AuTwelve weeks following hematopoietic reconstitution, we
measuredGFP+ andmCherry+ cells within specific hematopoiet-
ic subsets in the bone marrow, thymus, and spleen of recipient
mice. Although the Brd4.552 hairpin generally performs more
strongly in in vitro mouse embryonic fibroblast (MEF) depletion
assays (Zuber et al., 2011b), both shRNAs caused similar levels
of Brd4 knockdown in retrovirally transduced stem and progen-
itor cells (Figure S1A), and thus we focused our analysis on sta-
tistically significant changes observed with both shRNAs. In all
tissues analyzed, Brd4 silencing caused depletion of T lymphoid
cells, includingCD4+ andCD8+ single-positive T-lineage subsets
(Figures 1B, 1C, and S1B). Both shRNAs also caused a signifi-
cant reduction in Lineage Sca1+ cKit+ hematopoietic stem cells
in reconstituted bone marrow (Figure 1D). Thus, in addition to
its demonstrated activity against hematopoietic malignancies,
sustained Brd4 suppression can adversely influence normal
hematopoiesis.
Construction of shBrd4 Transgenic Mice
To further explore the consequence of Brd4 suppression
on normal (nonhematopoietic) tissues, we developed Brd4-
targeted shRNA transgenic strains, which enable the inducible
and reversible silencing of Brd4 in vivo. Our laboratory has pre-
viously reported the generation of transgenic shRNA mice using
recombinase-mediated cassette exchange that direct single-
copy transgenic integrations downstream of the Collagen type
I gene (Col1a1) (Dow et al., 2012; Premsrirut et al., 2011). Using
this approach, we generated transgenic mice carrying Brd4.552,
Brd4.1448, or control Ren.713 shRNAs, linked to GFP, under
the control of the TRE-tight promoter (hereafter referred to as
TtG-Brd4.552, TtG-Brd4.1448, and TtG-Ren.713).
To validate Brd4 knockdown in this system, double-transgenic
R26-rtTA; TtG-Brd4.552 mouse embryo fibroblasts were gener-
ated and cultured in the presence of dox for 4 days. Brd4 west-
ern blots on nuclear extracts from unsorted and sorted GFP+
and GFP cells showed a marked reduction of Brd4 protein in
only GFP+ (shBrd4-expressing) cells (Figure 2A). Brd4 silencing
in AML cells causes suppression of c-Myc expression (Zuber
et al., 2011b); however, despite potent knockdown, we did not
observe any changes inMyc protein levels following Brd4 knock-
down in MEFs (Figure 2A). Similarly, substantial in vivo Brd4
knockdown was observed in thymus extracts from mice fed
the dox diet for 2 weeks. Likewise, in thymus tissue, basal Myc
protein levels remained largely unchanged (Figure S2A). Collec-
tively, these results indicate that shBrd4 transgenes can effec-
tively suppress Brd4 protein in vitro and in vivo and that Brd4
is not invariably required for Myc expression.
Next, we examined the consequences of sustained Brd4
knockdown in adult tissues by initiating Brd4 silencing in 3- to
5-week-old mice. R26-rtTA; TtG-Brd4 animals did not display
any overt phenotype following 4 weeks of doxycycline treatment
despite uniform GFP (and Brd4 shRNA) expression in the skin,
small and large intestine, and thymus (Figure S2B). In order to in-
crease the efficiency of Brd4 silencing, we crossed the TtG-Brd4
alleles to mice harboring a CAG-rtTA3 transgene, which pro-
duces stronger and more ubiquitous target gene knockdown
(Premsrirut et al., 2011) (Figure S2C). Indeed, when double-
transgenic CAG-rtTA3; TtG-shRNA mice were fed a dox diet,thors
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Figure 1. Brd4 Knockdown Affects Normal Hematopoiesis
(A) Schematic representation the of reconstitution assay. Hematopoietic stem and progenitor cells (HSPCs) from CD45.2+ mice were retrovirally transduced to
express a neutral control shRNA against Renilla luciferase (shRen.713-Cherry+) or an experimental shRNA (GFP+). Infected populations were mixed at 1:1 ratio
and transplanted into lethally irradiated CD45.1+ recipients. Hematopoietic lineages within the spleen, thymus, and bonemarrowwere examined for the presence
of Cherry+ and GFP+ donor-derived cells 12 weeks posttransplantation. An shRNA against replication protein A3 (shRpa3.455) serves as a strong positive control
for depletion. Two independent shRNAs targeting Brd4 (shBrd4.1448 and shBrd4.552) were used.
(B–D) Thymus (B), bone marrow lineage (C), and bone marrow stem cell composition (D). The percentage of CD45.2+ cells expressing shRen.713 (red) and the
indicated experimental hairpin (green) in specific hematopoietic lineages (B220+ B cells, CD3+ T cells and CD4/CD8 T cell subsets, Ter119+ erythroid cells and
Gr1+ granulocytes) are shown. In addition, myeloid progenitors (LK: Lineage, cKit+, Sca1) and hematopoietic stem cells (LSK: Lineage, cKit+, Sca1+) are
shown. Data are presented as mean + SEM (n = 4). Asterisks (*) indicate a statistically significant difference between the presence of neutral control and
experimental shRNAs (p < 0.05), as determined by a two-tailed Student’s t test.
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Figure 2. Characterization of Transgenic shBrd4 Mice
(A) Immunoblot for Brd4 and c-Myc expression in nuclear extracts from R26rtTA/+; TtG-shBrd4.552MEFs treated for 4 days with doxycycline (1 mg/ml). MEFswere
sorted on the basis of GFP expression or left unsorted. Asterisk (*) denotes a nonspecific band detected in MEF extracts. Ponceau S stains indicate protein
loading.
(B) Mean weight changes (g) of male and female (combined) CAGrtTA3/+; TtG-Brd4.552mice on the dox diet, relative to day 0 of dox treatment. Littermate controls
include double-transgenic CAGrtTA3/+; TtG-Ren.713 mice and single-transgenic mice that carry a TtG-shRNA but lack a tet-transactivator. Error bars represent
SEM (n = 6).
(C) Image of a CAGrtTA3/+; TtG-Brd4.552 and littermate control CAGrtTA3/+; TtG-Ren.713 mouse treated with doxycycline for 5 weeks.
(D) Immunofluorescence analysis of GFP and Brd4 in dorsal skin sections from CAGrtTA3; TtG-shRNA mice. Arrows indicates the dermal papilla, where shRNAs
fail to be expressed (GFP negative) and Brd4 expression is thus retained in CAGrtTA3/+; TtG-Brd4 mice.GFP expression was additionally observed in the pancreas,
stomach, and seminal vesicles and GFP expression was
substantially brighter in the skin, small intestine, and lower
gastrointestinal tract (Figure S2B). Double-transgenic CAG-
rtTA3; TtG-Brd4.552 mice showed a mild, but not significant,
reduction in weight gain over 2 weeks compared to control
CAG-rtTA3; TtG-Ren.713 mice, indicating that potent Brd4 sup-
pression was not immediately toxic (Figures 2B and S3A), unlike
the severe weight loss that has been reported in other transgenic
shRNA strains targeting essential genes (McJunkin et al., 2011).
CAG-rtTA3; TtG-Brd4.552 mice maintained on dox for 5 weeks
showed a significant decrease in weight gain (Figure 2B), and
although we did not observe the same consistent difference1922 Cell Reports 8, 1919–1929, September 25, 2014 ª2014 The Auwith the Brd4.1448 shRNA, some animals showed reduced
weight gain and eventual weight loss (Figure S3A). This differ-
ence perhaps suggests that slight variations in Brd4 levels could
have a significant functional impact, but it is possible that other
complications arising from Brd4 depletion influenced the health
of these animals.
Brd4 Silencing Produces Skin Hyperplasia
Sustained Brd4 silencing induced striking phenotypic changes
in the skin. Within 5 weeks of dox treatment, shBrd4 mice
displayed follicular dysplasia characterized by abnormal hair
growth and subsequent alopecia (Figures 2C and S3B), whereas
control mice maintained on dox, and CAG-rtTA3; TtG-Brd4 micethors
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Figure 3. Brd4 Suppression Promotes Epithelial Hyperplasia and Follicular Defects in the Skin
(A) Representative hematoxylin and eosin (H&E) and immunofluorescent stains of dorsal skin sections from CAGrtTA3/+; TtG-Ren.713 and CAG rtTA3/+;
TtG-Brd4.552mice on the dox diet for 2 weeks, showing hair shaft defects and epithelial hyperplasia. The bottom panels show dorsal skin sections in CAGrtTA3/+;
TtG-Brd4.552 mice following 5 weeks of dox treatment and 2 weeks of subsequent dox withdrawal. Scale bars are indicated.
(B) Image of a CAGrtTA3/+; TtG-Brd4.552 and littermate control CAGrtTA3/+; TtG Ren.713 mouse following 5 weeks of doxycycline treatment and 2 weeks of
subsequent dox withdrawal.
(C) Full-thickness scans of H&E-stained dorsal skin sections fromCAGrtTA3/+; TtG-Ren713 and CAGrtTA3/+; TtG-Brd4.552mice after 2 weeks of dox treatment (left
and middle) and CAGrtTA3/+; TtG-Brd4.552 skin after 5 weeks of dox treatment and dox withdrawal (right).maintained on a normal diet (data not shown), were phenotypi-
cally normal. Immunofluorescence analyses of skin sections
from control mice showed that Brd4 was robustly expressed in
the outermost layer of the inner root sheath, in the epidermis
(basal and first suprabasal layer), and at the base of the hair fol-
licle, including the dermal papillae (Figure 2D). Dox-fed CAG-
rtTA3; TtG-Brd4 mice showed strong GFP expression and
Brd4 silencing in the hair follicle and epidermis (Figure 2D). Of
note, small regions within the dermal papilla did not expressCell Rethe GFP-linked shRNA and retained Brd4 expression. While it
is unclear what accounts for the lack of transgene induction in
these cells, it occurred in both shRen control and shBrd4 ani-
mals, suggesting a technical issue rather than active silencing
of the Brd4 shRNA.
Consistent with the expression pattern, Brd4 silencing induced
hyperplasia in the epidermis and hair follicles, with orthokeratotic
hyperkeratosis and moderate follicular keratosis (Figures 3A and
S3C). Hair shafts were frequently deformed, including shafts thatports 8, 1919–1929, September 25, 2014 ª2014 The Authors 1923
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Figure 4. Brd4 Suppression Results in Loss
of Intestinal Cellular Diversity
(A) Immunohistochemical staining showing GFP
expression (brown) in intestines of shBrd4 mice
on the dox diet. Tissues were counterstained with
hematoxylin.
(B) Western blot of Brd4 protein levels in intestinal
villi from CAGrtTA3-expressing TtG-Ren.713, TtG-
Brd4.552, and TtG-Brd4.1448mice, maintained on
a dox diet for 2 weeks.
(C) Histological and immunohistochemical stains
of small intestine sections from CAGrtTA3-
expressing TtG-Ren.713, TtG-Brd4.552, and TtG-
Brd4.1448 mice. Included are H&E stains (where
arrows indicate the location of eosinophilic gran-
ules of Paneth cells), immunofluorescent stains
for BrdU incorporation (marking proliferating
cells) and Keratin 20 (KRT20-differentiated cells),
immunohistochemical staining for Lysozyme
(Paneth cells), in situ hybridization for Olfm4 (in-
testinal stem cells), and Alcian blue stains (goblet
cells). Scale bars are indicated.were wavy (zigzag), bent, giant, or attenuated, and hair follicles
were more numerous, diverse in size, dilated, and often empty,
with concomitant increases in the size of sebaceous glands.
Brd4 suppression resulted in multiple layers of cytokeratin 6
(CK6)-positive cells along the inner root sheath, and we noted
expanded E-cadherin expression uponBrd4 knockdown, indica-
tive of hyperplasia and substantial defects in cellular architecture1924 Cell Reports 8, 1919–1929, September 25, 2014 ª2014 The Authorsthroughout the follicular and epidermal
epithelium (Figures 3A and S3D). Impor-
tantly, the skin phenotype presented
similarly in the two independent shBrd4
strains, suggesting a bona fide on-target
effect of Brd4 suppression.
In our tet-regulated shRNA mice, Brd4
expression can be restored through
removal of dox, allowing us to examine
whether the observed skin effects are
permanent or reversible. For this, TtG-
Brd4 and littermate control mice were
maintained on a dox diet until alopecia
developed (5–7 weeks) and then returned
to normal chow. Within 2 weeks following
Brd4 restoration, hair growth was fully
restored, hair shaft abnormalities disap-
peared, and histologic parameters of
follicular and epidermal epithelia returned
to normal (Figures 3A–3C and S3E). Thus,
the skin phenotypes produced by sus-
tained Brd4 suppression are rapidly
reversible.
Brd4 Silencing Depletes Secretory
Cells and Lgr5+ Stem Cells in the
Intestine
Due to its high proliferative rate, the
intestine is a common site of chemo-therapy-associated toxicities. In CAG-rtTA3; TtG-Brd4 double-
transgenic mice, the intestinal epithelium showed robust
expression of GFP and suppression of Brd4 protein (Figures
4A, 4B, and S2C). In contrast to the dramatic hyperplastic
response observed in the skin, the proliferation and differentia-
tion of the intestine (indicated by bromodeoxyuridine [BrdU]
incorporation and Keratin 20 staining) looked superficially
normal (Figure 4C). Still, while moderate Brd4 silencing driven by
R26-rtTA did not cause any disruptions to the intestinal compo-
sition (Figure S4A), strong Brd4 suppression with CAG-rtTA3 led
to a marked depletion of eosinophilic-granule-containing Lyso-
zyme+ Paneth cells at the base of the intestinal crypts, fewer
and smaller Mucin+ goblet cells (Figure 4C), and a complete
lack of Dclk1+ Tuft cells (Figure S4B). This clear difference im-
plies that the level of Brd4 suppression required to induce intes-
tinal phenotypes lies somewhere in between that produced by
R26-rtTA and CAG-rtTA3 (Figure S2C).
In addition to the depletion of secretory lineage populations in
CAG-rtTA3; TtG-Brd4 mice, Brd4 suppression caused a loss of
Olfm4+/Lgr5+ stem cells at the base of intestinal crypts (Figures
4C and S4B). Disruption of the crypt and loss of Paneth cells was
apparent within 8 days of dox treatment, sustainable for multiple
weeks and presented similarly in both shBrd4 strains, implying it
was a direct result of Brd4 suppression (Figure S4C). Notably, no
changes in proliferation or apoptosis in the base of intestinal
crypts were detected upon Brd4 depletion (Figures S4D and
S4E), raising the possibility that Brd4 may control lineage spec-
ification in the gut rather than survival of specific cell types.
Brd4 Knockdown Suppresses Organoid Formation
To determine whether the decrease in Olfm4 and Lgr5 staining in
shBrd4mice reflectedasimple lossof gene expressionor a lossof
functional stemcells,weuseda recentlydescribed intestinal crypt
‘‘organoid’’ culture system (Sato et al., 2011). In this ex vivo culture
system, organoid-forming ability is directly related to the func-
tionality of Lgr5+ stem cells and niche-supporting Paneth cells
(Durand et al., 2012, Sato et al., 2011). Consistentwith a reduction
in stem cell numbers, crypts isolated from shBrd4 mice on dox
for 2 weeks could not form proliferative intestinal organoids
compared to crypts from control mice (Figures 5A, 5B, S5A, and
S5B). Impaired organoid formation was most apparent when
crypts were maintained in the presence of dox ex vivo but was
also significantly reduced when crypts from dox-treated mice
were cultured in the absence of dox, suggesting that reduced col-
ony-forming ability was largely established prior to crypt explant.
The substantial pathologies associated with Brd4 silencing are
apparently at odds with the limited toxicities reported for BET in-
hibitors to date. Indeed, treatment of control C57Bl/6 mice with a
pharmacological BET inhibitor (JQ1, once daily, 100mg/kg intra-
peritoneally) for 2 weeks did not induce changes in the histolog-
ical appearance of the small intestine or loss of Paneth cells
(Figure S5C). Consistent with this, treatment of mice with JQ1
for 2 weeks had no detrimental effect on organoid-forming ability
(not shown). It is not clear whether the different effects of shBrd4-
mediated knockdown and JQ1 treatment on the intestine arise
from intrinsic differences between Brd4 protein depletion and
small-molecule BET inhibition or from poor drug stability/tissue
delivery in vivo; JQ1 is known to have poor pharmacokinetic
properties in vivo (Matzuk et al., 2012). However, ex vivo treat-
ment of freshly isolated wild-type crypts with JQ1 (100 nM)
strongly suppressed organoid formation (Figures 5C and 5D),
similar to the effect of RNAi-mediated Brd4 suppression in vivo.
Thus, both Brd4 suppression and small molecule BET protein in-
hibition (with JQ1) have similar effects on crypt health ex vivo,
under conditions where drug delivery is not limiting.Cell ReTo examine whether Brd4 silencing initiates a permanent
change in stem cell function in the intestine, we treated TtG-
Brd4 mice with dox for 2 weeks (when stem cell depletion is
apparent), then removed dox to restore endogenous Brd4
expression (Figure 5E) and isolated intestinal crypts. Similar to
what we observed in the skin, 2 weeks following dox withdrawal,
crypts from shBrd4 mice appeared histologically normal, reac-
quired Paneth cells, goblet cells, and Olfm4+ stem cells (Figures
5F and 5G). Most importantly, the crypts from Brd4-restored
animals contained functional stem cells that allowed efficient
organoid formation in explant culture, indistinguishable from
TtG-Ren.713 control mice (Figures 5A and 5B). Thus, while
Brd4 silencing induces depletion of multiple cell types in the
intestine, the effects are rapidly reversible, implying that the
consequences of BET protein inhibition could be managed by
appropriate dosing.
Brd4 Suppression Sensitizes Mice to Radiation-Induced
Intestinal Damage
The relative fitness of mice in which Brd4 was suppressed was
surprising given the dramatic changes in intestinal cell composi-
tion. Nonetheless, such defects might reduce the ability of the
intestine to recover in response to stress, for example, as might
occur in response to cytotoxic therapies used to treat cancer. In
fact, Lgr5+ crypt stem cells are critical for recovery from radia-
tion-induced intestinal damage (Metcalfe et al., 2014). Similarly,
the chemotherapeutic drug Adriamycin (doxorubicin hydrochlo-
ride), commonly used to treat AML, also induces intestinal dam-
age, although in this case Lgr5+ stem cells are thought to play a
less critical role in recovery (Dekaney et al., 2009). To determine
whether shBrd4 mice were susceptible to intestine regenerative
challenge posed by DNA-damaging-agent exposure, we treated
control and TtG-Brd4 mice with dox for 2 weeks and induced
acute DNA damage with either a single sublethal dose (9 Gy)
of g-radiation or a well-tolerated, single dose (10mg/kg) of doxo-
rubicin (Figure 6A).
Upon treatment with irradiation, we observed strikingly
different outcomes in shBrd4 and control mice on dox. TtG-
Ren.713control animals showed transientweight lossassociated
with intestinal damage (FigureS6A)but stabilized4days following
irradiation, accompaniedby characteristic intestinal regeneration
and expansion of the proliferative crypt compartment (Figures 6B
and 6C). Six days following irradiation, the intestines of control
animals lookednormal. In stark contrast,Brd4-silenced intestines
showed irregular, atrophied villi and inconsistent proliferative
crypt recovery (Figures 6B, 6C, and S6B). Unlike control mice,
Brd4-depleted animals continued to lose weight, owing to an
inability to restore the absorptive epithelia, and most animals
had to be sacrificed (Figures 6D and S6A). In combination with
doxorubicin, Brd4-depletedmice demonstrated slightly impaired
weight gain relative to control mice over the 7-day time period
following the doxorubicin treatment (Figure S6C), suggestive of
amild defect in full recovery of intestinal function.However, histo-
logical examination of intestines did not indicate an effect on
overall tissue integrity or differences in proliferative responses
of control andshBrd4groupsat this doseof doxorubicin, possibly
pointing to a more subtle defect (Figure S6D). Collectively, these
data suggest that potent depletion of Brd4 impairs the ability ofports 8, 1919–1929, September 25, 2014 ª2014 The Authors 1925
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Figure 5. Brd4 Suppression by RNAi and JQ1 Inhibits Intestine Organoid Formation
(A) Representative images of intestine crypt cultures fromCAGrtTA3-expressing TtG-Ren.713 and TtG-Brd4.552mice. Animals were fed a dox diet for 2 weeks and
intestine crypts maintained on dox in vitro (left), crypts cultured off dox in vitro (center), or animals were fed dox-diet for 2 weeks, withdrawn for 2 weeks, and
maintained off dox in vitro (right).
(B) Quantification of organoid-forming efficiency for cultures shown in (A).
(C) Representative images of C57Bl/6 intestine crypts when cultured in the presence of DMSO or 100 nM JQ1.
(D) Quantification of organoid-forming efficiency for crypt cultures shown in (C).
(E) Western blot of Brd4 protein levels in intestinal villi from CAGrtTA3-expressing TtG-Ren.713, TtG-Brd4.552, and TtG-Brd4.1448 mice, maintained on a dox diet
for 2 weeks (+) or treated with dox for 2 weeks and withdrawn for 2 weeks (+/). The expression of GFP and b-Actin are also shown.
(F) H&E, BrdU, Keratin 20 (KRT20), lysozyme (Paneth cell), OLFM4 (stem cell), and Alcian blue (goblet cell) staining of small intestine in CAGrtTA3-expressing TtG-
Ren.713 and TtG-Brd4.552 mice fed a dox diet for 2 weeks and in Brd4.552 mice following 2 weeks of dox withdrawal. Asterisks (*) indicate a statistically
significant difference between shRen.713 and shBrd4.552 organoid-forming efficiency (p < 0.05), as determined by two-tailed Student’s t test.
(G) Quantification of Alcian blue-positive goblet cells in CAGrtTA3-expressing TtG-Ren.713 and TtG-Brd4.552 mice after 2 weeks on dox and CAGrtTA3/+; TtG-
Brd4.552 mice taken off dox for 2 weeks. Error bars represent the mean of three independent samples ± SEM.
Data in (B) and (D) represent mean ± SD (nR 3).animals to fully respond tochallenges that trigger intestinal regen-
eration, although the level of combined toxicity will likely depend
on the type and dose of damaging agent.
DISCUSSION
The BET family protein Brd4 is a promising therapeutic target for
the treatment of cancer, and early-generation BET inhibitors are
being evaluated in phase 1/2 clinical trials. Here, we used RNAi
to explore the consequence of acute and potent Brd4 suppres-
sion in normal adult mouse tissues with the goal of predicting
potential on-target toxicities associated with Brd4-targeted1926 Cell Reports 8, 1919–1929, September 25, 2014 ª2014 The Autherapies in the clinic. More generally, the transgenic RNAi tech-
nology employed in our study enables us to spatially and revers-
iblymodulate endogenous gene expression, a feature that allows
us to explore an aspect of biology that cannot be easily achieved
with traditional knockout mouse models. Consequently, this
approach can be applied to explore the requirement for any po-
tential drug target in normal tissuedevelopment andmaintenance
(therebypredicting side effects and susceptible tissues/organsof
pharmacological inhibitors prior to clinical application).
In this study, the impact of potent Brd4 silencing in vivo was
remarkably diverse.We observed dramatic and opposing effects
on proliferation, differentiation, and the homeostasis of differentthors
AB
C
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Figure 6. Brd4 Silencing Impairs Intestinal
Regeneration following Irradiation
(A) Schematic representation of the experi-
mental timeline. Animals were treated with dox
for 2 weeks and given a single, 9 Gy dose of
g-radiation.
(B and C) H&E (B) and Ki67 (C) stains of small in-
testine sections from CAGrtTA3-expressing TtG-
Ren.713 and TtG-Brd4.552 mice 2, 4, and 6 days
following irradiation as indicated. Scale bars
represent 100 mm.
(D) Kaplan-Meier plot of dox-treated, irradiated
mice, beginning at day 0 of dox treatment. Dotted
line at day 14 indicates the day of irradiation.tissues of the same animal. In the hematopoietic compartment,
Brd4 silencing led to depletion of T lymphoid cells and Lineage
Sca1+ cKit+ hematopoietic stem cells. In the skin, Brd4 knock-
down caused significant architectural disruptions in the hair fol-Cell Reports 8, 1919–1929, Seplicles that manifested in dramatic hair
loss, while the epidermis showed hyper-
plasia, which was unexpected given the
published role for Brd4 in normal cell-cy-
cle progression (Dey et al., 2009; Yang
et al., 2008). By contrast, in the intestine,
we noted a substantial decrease in differ-
entiation toward secretory cell lineages
and a loss of functional stem cells.
Though this stem cell depletion had
limited effect under normal conditions,
Brd4-suppressed intestines were hyper-
sensitive to cytotoxic damage and could
not properly initiate or sustain intestinal
regeneration following irradiation. What
mediates these diverse phenotypes in
the skin and intestine is unclear, but it
possibly occurs through mechanisms
that are independent of the regulation of
Myc, as has been reported in other non-
hematopoietic contexts (Huang et al.,
2009; Lockwood et al., 2012).
Using our transgenic shRNA mice, we
focused our study on the intestine and
skin, as these were two organs in which
we could achieve strong, ubiquitous
shRNA expression from the TREtight
promoter and could therefore confi-
dently examine tissue-autonomous ef-
fects of Brd4 suppression. Unfortunately,
we were unable to express TREtight-
driven shRNAs in a number of tissues
(such as the liver) that we predict would
be affected by strong Brd4 knockdown
on the basis of the Brd4 heterozygote
phenotype reported by Beddington and
colleagues (Houzelstein et al., 2002).
Thus, the consequences of systemic
Brd4 depletion may be more numerousthan reported here, and further work will be required to fully
ascribe the role of Brd4 in all adult tissues.
Our study identified a range of potential on-target toxicities of
Brd4 depletion that were not anticipated from preclinical studiestember 25, 2014 ª2014 The Authors 1927
using first-generation BET inhibitors such as JQ1. Specifically, in
contrast to the apparent lack of impact of BET inhibitors on
normal hematopoiesis, we observed depletion in T lymphocytes
and stem cells. Furthermore, JQ1 treatment in our study did not
result in loss of intestinal stem, Paneth, and secretory cells,
which we consistently observed with our shRNA transgenic
mice. While it remains possible that inherent differences be-
tween RNAi-mediated knockdown and small-molecule inhibition
of Brd4 bromodomain function contribute to their differential
impact on the intestine in vivo, it seems possible that this
discrepancy can be explained by the poor pharmacokinetic
properties of JQ1, which may preclude sustained target inhibi-
tion in vivo (Matzuk et al., 2012). Accordingly, previous work in-
dicates RNAi and BETi induce similar gene expression changes
(Zuber et al., 2011b), and we show here that the impact of Brd4
shRNAs and JQ1 on intestinal crypt function in vitro is similar.
While we focused on normal tissues, it will be key to assess
whether the level and duration of Brd4 disruption reported here
to disrupt tissue homeostasis is required for meaningful thera-
peutic effects in tumors or whether an acceptable therapeutic
index of BET inhibitors can be achieved in the clinic.
Perhaps most relevant to their eventual clinical use, our data
suggest that potent Brd4 knockdown reduces the ability of
animals to respond to at least some intestinal regenerative chal-
lenges that might be encountered during combinatorial thera-
peutic application of DNA-damaging agents. As shown here,
the deleterious consequences of a particular combination will
depend on the cytotoxic agent and likely the extent of BET
protein inhibition. While the precise bases for these differences
remain to be determined, the potential for synergistic toxicities
for each combination should be examined carefully as combina-
tion trials are developed. Most importantly, however, the pheno-
typic consequences of Brd4 suppression appear completely
reversible upon restoration of Brd4 expression, implying that
any deleterious consequences of on-target Brd4 inhibition
observed clinically could be managed through careful timing of
drug administration and withdrawal.
EXPERIMENTAL PROCEDURES
Generation of ESC-Derived Mice
miR30-based shRNA targeting vectors were cloned as previously described
(Dow et al., 2012) The shRNAs used in this study are listed as XhoI/EcoRI frag-
ments in Table S1. Embryonic stem cells (ESCs) were targeted and screened
as described previously (Dow et al., 2012; Premsrirut et al., 2011, 2013) and
mice generated by tetraploid embryo complementation.
Transgenic Animals and Ethics Approvals
All experimental procedures described in this study were approved by, and
adhered to guidelines of, the Memorial Sloan-Kettering Cancer Center institu-
tional animal care and use committee. Doxycycline was administered to mice
via 625 mg/kg doxycycline-containing food pellets (Harlan Teklad).
Nuclear Protein Extraction and Western Blotting
Cytoplasmic proteins from single-cell suspensions of thymi were extracted
using hypotonic buffer and Triton X-100 followed by centrifugation. Nuclear
proteins were then extracted through incubation with hypertonic buffer
and quantified by DC protein assay (Bio-Rad). Intestinal villi were lysed in
Laemmli buffer. Protein extracts were separated by SDS-PAGE and trans-
ferred onto polyvinylidene fluoride membrane (Millipore) for detection with
antibodies.1928 Cell Reports 8, 1919–1929, September 25, 2014 ª2014 The AuImmunohistochemistry and Immunofluorescence
Murine tissues were fixed overnight in 10% neutral buffered formalin or fresh
4% paraformaldehyde. Antigen retrieval was performed in Tris buffer for all
immunohistochemical stains except for the detection of Lysozyme, where an-
tigen retrieval was achieved by proteinase-K. ImmPRESS horseradish perox-
idase-conjugated secondary antibodies together with ImmPact DAB (Vector
labs) were used for chromagen development. Tissues were counterstained
with hematoxylin. The general protocol for in situ hybridization for Olfm4
and Lgr5 were performed essentially as previously described (Gregorieff
et al., 2005). For immunofluorescence studies, antigen retrieval was performed
with citrate buffer. Slides were incubated overnight with primary antibodies
and counterstained with DAPI.
Intestine Crypt Isolation and Culture
Intestine crypt isolation and culture was done as previous described (Sato
et al., 2011). For determination of organoid-forming efficiency, freshly isolated
crypts were plated in triplicate and assessed 12 hr later to count viable crypts.
The same microscopic fields were examined at day 4 and the data were
normalized as relative crypt-forming efficiencies (proliferative organoids at
day 4/viable crypts at 12 hr).
Two-Color Competitive RNAi Assay and Hematopoietic
Reconstitution
Two-color in vivo RNAi hematopoietic reconstitution assays were performed
as described previously (Zuber et al., 2011a). Control (LMN-Cherry) and
experimental (LMN-GFP) shRNA populations were mixed 1:1 and injected
intravenously into recipient mice. Following hematopoietic reconstitution, the
spleen, thymus, and bone marrow were analyzed for the presence of GFP+
and Cherry+ fluorescence markers in specific hematopoietic lineages by
flow cytometry.
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